You are here

Home » Content

MELATONİN: EMEKLİLİK YAŞI 80 OLUR MU?

Melatonin: retiring at the age of 80 ?

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Although not licensed as a drug, melatonin, the principal substance secreted by the pineal gland, is marketed sold as a nutritional supplement in the USA for its purported sleep-promoting and antiaging properties. There is now evidence that melatonin may have a role in the biologic regulation of circadian rhythm, sleep, mood, and perhaps reproduction, tumor growth, and aging. However, uncertainties and doubts still surround the role of melatonin in human physiology ana pathophysiology. The purpose of this review is to summarize the current knowledge about melatonin and its clinical implications.
Bookmark/Search this post with
Abstract (Original Language): 
Pineal bezden salgılanan ana madde olan melatonin, ilaç olarak lisans almamış olmasına rağmen, ileri sürülen uyku verici ve yaşlanmayı geciktirici özelliklen nedeniyle, ABD'de besin katkı maddesi şek/inde yaygın olarak satılmaktadır. Bugün için, melatoninin, sirkadian ritmlerin, uykunun, ruhsal durumun ve belki üreme, tümör gelişimi ve yaşlanmanın biyolojik regülasyonunda rolü olabileceğine dait bulgular vardır. Ancak, melatoninin insan fizyolojisi ve patofizyolojisindeki rolüne ait belirsizlikler ve şüpheler hala mevcuttur. Bu derlemenin amacı, melatonin hakkında şu andaki bilgilerimizi ve klinik kullanımı ile ilgili beklenti ve yönelimleri özetlemektir.
FULL TEXT (PDF): 
PDF icon arastirmax-melatonin-emeklilik-yasi-80-olur-mu.pdf
  • 2
177-187
  • Turkish

REFERENCES

References: 

1- Klatz R, Goldman R. Stopping the clock. 2nd Ed, New York: Bantam Books. 1997: 27-47.
2- Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80: 2587.
3- Brzezinski A. Mechanisms of disease: Melatonin in humans. N England J Med 1997; 336 (3): 186-95.
4- Sack RL, Lewy AJ, Hughes RJ. Use of melatonin for sleep and circadian rhythm disorders. Ann Med 1998; 30 (1): 115-21.
5- Reiter RJ. The mammalian pineal gland: Structure and function. Am J Anat 1981; 162: 287-313.
6- Manev HT, Kharlamov A, Joo JY. Increased brain damage after stroke or excitotoxic seizures in melatonin deficient rats. FASEB 1996; 10 (13): 1546-51.
7- Waldhauser F, Dietzel M. Daily and annual rythms in human melatonin secretion: role in puberty control. Ann N YAcad Sci 1985; 453: 205-14.
8- Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994; 269: 28531-4.
9- Reiter RJ, Tan DX, Kim SJ, Wenbo QI. Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Proc West Pharmacol Soc 1998; 41: 229-36.
10- Wurthman RJ, Zhdanova I. Improvoment of sleep guality by melatonin. Lancet 1995; 346: 1491.
11- Haimow I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly imsomniacs. Sleep 1995; 346: 541-4.
12- Zhdanova I, Wurthman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-8.
13- Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. BMJ 1986; 292: 1170.
14- Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 1993; 33: 526-30.
15- 15-Worzniak DF, Stewart GR, Miller-Dawney JW. Brief communigation: Age-related sensitivity to kainat neurotoxicity. Exp Neurol 1991; 114: 250-3.
16-
Ayha
n K, Ahmet Ç. Melatonin ve santral sinir sistemi. Turgut Özal Tıp Merkezi Dergisi 1996; 3 (3): 237-44.
17- Golombek DA, Pevet P, Cardinali DP. Melatonin effects on behevior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996; 20 (3): 403-12.
18- Bubenik GA, Blask DE, Brawn GM, Maestroni GJ, Pang SF, Reiter RJ, Vinswanathan M, Zisapel N. Prospecst of the clinical utilization of melatonin. Biol Signals Recept 1998; 7 (4): 195-219.
19- Ebadi M, Gavitrapong P, Phansuwan-Pujito P, Nelson F, Reiter RJ. Pineal opioid receptors and analgesic action of melatonin. J Pineal Res 1998; 24 (4): 193-200.
20- Reiter RJ, Guerrero JM, Garcia JJ, Castroviejo DA. Reactive oxygen intermediates molecular damage and aging: Relation to melatonin. Ann NY Acad Sci 1998; 854: 410-24.
21- Pierpaoli W, Regelson W. Pineal control of aging: Effect of melatonin and pineal grafting on aging mice. Proc Natl Acad Sci USA 1994; 91: 787-801.
22- Lenz SP, Izui S, Benediktson H, Hart DA. Lithium chloride enhances survival of NZB/W lupus mice: influences of melatonin and timing of treatment. Int J Immunopharmacol 1995; 17: 581-92.
23- Oaknin-Bendehan S, Anis Y, Nır I, Zisapel N. Effect of long term administration of melatonin and a putative antagonist on the aging rat. Neuroreport 1995; 6: 785-8.
24- Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-demethylbenz(a)anthtacene-induced mammary tumors in the rat. Cancer Res 1981; 41: 4432-6.
25- Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellman O, Gupta D. Stage dependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, thyroid stimulating hormone and steroid receptor. Cancer 1989; 64: 426-33.
26- Bartsch C, Bartsch H, Schmidt A, lig S, Bichler KH, Fluchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhytms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209: 153-67.
27- Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptor for 28- melatonin: antiproliferatif effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 1993; 246: 89-96.
29- Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compered to radiotherapy alone. Oncology 1996; 53: 43-6.
30- Lissoni P, Meregalli S, Barni S, Frigerio F. A randomized study of immunotherapy with low-dose subcutaneus Interleukin-2 plus melatonin vs. chemotherapy with Cisplatin and Etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994; 80: 464-7.
31- Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity: Melatonin enhances the antibody response via an opiatergik mechanism. Clin Exp Immunol 1987; 68 (2): 384-91.
32- Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment counteracts glucocorticoid-induced disregulation of the hypotalamic-pituitary-adrenal axis in the rat. Neuroendocrinol 1998; 67 (3): 171-80.
33- Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El-Sokkary GH. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: Prevention by melatonin. J Pin Res 1998; 25: 184-91.
34- Lastra DL, Cabeza CAJ, Montilla V, Martın MJ. Melatonin protects against gastric ischemia-reperfusion injury in rats. J Pin Res 1997; 23: 47-52.
35- Sewerynek E, Reiter RJ, Melchıorrı D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology 1996; 43: 898-905.
36- Del Zar MM, Martinuzzo C, Falcon C, Cardınalı DP, Carreras LO, Vacas MI. Inhibition of human platelet aggregation and tromboxane-B2 production by melatonin: evidence for a diurnal variation. J Clin Endocrinol 1990; 70: 246-51.
37- Reiter RJ. Oxidative damage in the central nervous system: Protection by melatonin. Prog Neurobiol 1998; 56: 359-84.
38- Kilic E, Özdemir YG, Bolay H, Keleştimur H, Dalkara T. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab 1999; 19: 511-16.
39- Voordouw BCG, Euser R, Verdonk RER, et al. Melatonin and melatonin progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74: 108-17.
40- Webley GE, Luck MR. Melatonin directly stimulates the secretion of progesterone by human and bovine granulosa ceels in vitro. J Reprod Fertil 1986; 78: 711-7.
41- Cagnacci A. Melatonin in relation to physiology in adult humans J Pin Res 1996; 21:200-13.
42- Laitinen JT, Viswanathan M, Vakkuri 0, SaavedraJM. Differential regulation of the rat melatonin receptors: Selective age associated decline and lack of melatonin induced-changes. Endocrinol 1992; 130: 2139-44.
43- Cagnacci A, Soldani R, Yen SSC. Hypothermic effect of melatonin and nocturnal core body temperature decline are reduced in aged women. L Appl Physiol 1995; 78: 314-7.
44- Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. JAMA 1996; 276 (13): 1011-4.
45- Cagnacci A, Angiolucci SM, Arangino-Elongu G, Melis GB. Influence of melatonin administration on the circulation of women. Am J Physiol 1998; 274: 335-8.
46- Reiter RJ. The aging pineal and its physiological consequences. BioEssays 1992; 14: 169-75.
47- Muller JE, Ludmer PL, Wilhch SN, Tofler GH, Aylmer G, Klangos I, Stone PH. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75:131-8.
48- Marktl W, Brogger P, Herold M. Melatonin and coronary heart disease. Wien Clin Wochenschrift.1997; 109: 747-9.
49- Laflammer K, Wu S, Foucart AL, Champlain DJ. Impaired basal sympathetic tone and alpha-1 adrenergic responses in assocation with the hypotensive effect of melatonin in spontaneously hypertensive rats. Am J Hypertens 1998; 11: 219-29.

Thank you for copying data from http://www.arastirmax.com